Benjamin P. Saylor


Saylor is content managing editor for Urology Times.


How Sanofi’s discontinuation of BCG affects patients, clinicians

December 27, 2016

Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.

Peri-op transfusion raises short-term morbidity risk

May 06, 2016

A retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.

AUA 2016: Experts offer guidance on the meeting

April 18, 2016

To guide you through the 2016 AUA annual meeting and help maximize your time, Urology Times’ editorial board has reviewed the program to identify the key trends and noteworthy research at this year’s meeting.

Uro Pipeline: Trial launched for drugs' use in metastatic, hormone-sensitive PCa

April 15, 2016

A novel oral TRT agent, bladder control system, and localized prostate cancer agent are among other treatments in the pipeline discussed in this round-up.